Apollo Hospitals' Financial Outlook

Apollo Hospitals' financial performance for the fourth quarter of fiscal year 2026 is expected to show year-on-year growth, indicating continued underlying strength. However, forecasts reveal a sequential dip in profitability and revenue. This suggests that post-pandemic recovery trends might be easing, while broader industry challenges are beginning to increase.

Analyst Forecasts Show Strong YoY Growth

ICICI Securities projects Apollo Hospitals will report a net profit of Rs. 474 crore for the January-March 2026 quarter, a 21.7% rise from the prior year. Net sales are forecast to hit Rs. 6,386.4 crore, up 14.2% year-on-year, with EBITDA expected to grow 19.1% year-on-year to Rs. 916.5 crore. However, these projections show a sequential decline from the previous quarter: net profit is estimated to drop 8.3%, net sales by 1.4%, and EBITDA by 5.1%. As of April 23, 2026, Apollo Hospitals' stock traded near Rs. 7,781.00, with a market capitalization of about Rs. 1.11 lakh crore. Investor sentiment following the official earnings release will be closely watched.

Sector Pressures and Apollo's Position

Apollo Hospitals' expected year-on-year growth aligns with a positive trend in the Indian healthcare sector, but the sequential slowdown needs attention. Competitors like Fortis Healthcare (expected Q4 FY26 revenue Rs. 2,000–2,150 crore, PAT Rs. 160–200 crore), Max Healthcare Institute (revenue Rs. 2,300–2,500 crore, PAT Rs. 330–380 crore), and Narayana Hrudayalaya (revenue Rs. 1,550–1,650 crore, PAT Rs. 185–215 crore) are also reporting growth. While Apollo's year-on-year figures look strong, the sequential dip differs from some peers who may show more stable quarter-on-quarter trends. The sector faces pressures from rising raw material and logistics costs, partly due to geopolitical events. The loss of exclusivity for key drugs in the pharmaceutical segment also signals wider cost pressures that could affect healthcare services through supply chain impacts. Apollo Hospitals' average revenue per occupied bed (ARPOB) growth has slowed to an estimated 8–10% in FY26, down from 15–18% in FY23-24, as growth from premium patient mix levels off. This slowdown, alongside a current P/E ratio around 60x, places Apollo at a higher valuation compared to some peers, though some analysts view it as reasonable within the sector. Analyst sentiment is largely positive, with a consensus 'Strong Buy' rating and average price targets around Rs. 8,700-8,800, suggesting potential upside.

Concerns Over Valuation and Sequential Slowdown

While Apollo Hospitals' forecasts show year-on-year improvement, the sequential slowdown is a key risk. The company's P/E ratio, around 60-72x, is high for hospital stocks globally. This valuation relies on continued strong growth, but recent ARPOB expansion trends suggest the growth path may be slowing, especially in premium segments. Any earnings miss in the upcoming quarter could lead to a significant valuation decrease. Apollo's ability to manage industry-wide margin pressures, such as increased freight and raw material costs, will be critical. Planned capacity expansions, aimed at long-term growth, require significant investment and effective execution to ensure profitability, especially as patient mix and pricing power are closely watched.

Analyst Sentiment and Future Watchpoints

Analysts maintain a positive outlook for Apollo Hospitals, with a consensus 'Strong Buy' rating and average 12-month price targets indicating potential upside of over 10-14%. The projected revenue and profit growth for the coming quarters are supported by ongoing capacity expansions and strong demand for healthcare services in India. Key areas investors will watch include management's guidance for the next fiscal year, its strategy for maintaining profit margins amid rising costs, and the successful integration of new facilities to support the current high valuation.